Buserelin

Phase 3Small molecule

NNCIC Clinical Trials Group

Buserelin is one of 55 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Prostate Adenocarcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

5 2

Lupron

Sun Pharmaceutical Industries, Inc.

Approved

3 3

Xtandi

Astellas

Approved

3 4

Nubeqa

Bayer

Approved

2 5

Jevtana

Sanofi

Approved

1 6

Firmagon

Ferring

Approved

5 7

Casodex

IIstituto Clinico Humanitas

Approved

5 8

Truqap

Thalomid

Nexavar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT05050084

Q4 2038

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT04513717

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002633·361 enrolled

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00651326·48 enrolled

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00054106·25 enrolled

Show 1 more trial

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003653·1,386 enrolled

Prostate Adenocarcinoma2 trials

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Ovarian Reserve1 trial

Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles

Terminated·AAndros Day Surgery Clinic·Phase 4·NCT01816789·194 enrolled

Flare up1 trial

Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders

Completed·—·Phase 4·NCT01213147·159 enrolled

Frozen Embryo Transfer1 trial

Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification

Unknown status·YYazd Research & Clinical Center for Infertility·Phase 1/2·NCT00823121·500 enrolled

1 more indication

Unspecified1 trial

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Completed·YYazd Research & Clinical Center for Infertility·Phase 4·NCT00830492·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Buserelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buserelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buserelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NCIC Clinical Trials Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNCIC Clinical Trials Group

Buserelin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Q4 2038

Trials by Indication[1]

Prostate Cancer4 trials

Prostate Adenocarcinoma2 trials

Ovarian Reserve1 trial

Flare up1 trial

Frozen Embryo Transfer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News